Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.

Breast cancer research and treatment - 1 Nov 2018

Borrie Adrienne E, Rose Rhiannon V, Choi Yun-Hee, Perera Francisco E, Read Nancy, Sexton Tracy, Lock Michael, Vandenberg Theodore A, Hahn Karin, Dinniwell Robert, Younus Jawaid, Logan Diane, Potvin Kylea, Yaremko Brian, Yu Edward, Lenehan John, Welch Stephen, Tyndale Rachel F, Teft Wendy A, Kim Richard B

Abstract excerpt

PURPOSE: The aromatase inhibitor (AI) letrozole is a first-line drug in the adjuvant treatment of breast cancer in postmenopausal women. Adherence to AI therapy, including letrozole, remains problematic due to the development of debilitating AI-induced arthralgia. Letrozole is metabolized in the liver by CYP2A6. It remains unknown if plasma letrozole levels or CYP2A6 genetic variation is associated with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Hormonal

Share to Aromatase Inhibitors

Share to Arthralgia

Share to Breast Neoplasms

Share to Cytochrome P-450 CYP2A6

Share to Genotype

Source

Identifiers

PMID: 30094551
DOI: 10.1007/s10549-018-4910-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.PMID 30094551Read ↗

Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.Semantic proximity Read ↗

Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.Semantic proximity Read ↗

Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity.Semantic proximity Read ↗

Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.Semantic proximity Read ↗

The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.Semantic proximity Read ↗

Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.Semantic proximity Read ↗

Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.Semantic proximity Read ↗

Pharmacogenetics of endocrine therapy for breast cancer.Semantic proximity Read ↗

Pharmacogenomics of third-generation aromatase inhibitors.Semantic proximity Read ↗

Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.Semantic proximity Read ↗

CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Semantic proximity Read ↗

Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.